How Novel Genetic Medicines may improve treatment of chronic Neurological Diseases
Update: 2025-11-11
Description
In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery.
EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
